315 related articles for article (PubMed ID: 32823598)
1. Low-Level Ionizing Radiation Induces Selective Killing of HIV-1-Infected Cells with Reversal of Cytokine Induction Using mTOR Inhibitors.
Pinto DO; DeMarino C; Vo TT; Cowen M; Kim Y; Pleet ML; Barclay RA; Noren Hooten N; Evans MK; Heredia A; Batrakova EV; Iordanskiy S; Kashanchi F
Viruses; 2020 Aug; 12(8):. PubMed ID: 32823598
[TBL] [Abstract][Full Text] [Related]
2. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
3. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/β-catenin/TCF1 axis in CD4
Wen J; Li X; Zhao QX; Yang XF; Wu ML; Yan Q; Chang J; Wang H; Jin X; Su X; Deng K; Chen L; Wang JH
Emerg Microbes Infect; 2022 Dec; 11(1):391-405. PubMed ID: 34985411
[No Abstract] [Full Text] [Related]
5. Curaxin CBL0137 has the potential to reverse HIV-1 latency.
Jean MJ; Zhou D; Fiches G; Kong W; Huang H; Purmal A; Gurova K; Santoso NG; Zhu J
J Med Virol; 2019 Aug; 91(8):1571-1576. PubMed ID: 30989696
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
7. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
8. Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4
Cao S; Slack SD; Levy CN; Hughes SM; Jiang Y; Yogodzinski C; Roychoudhury P; Jerome KR; Schiffer JT; Hladik F; Woodrow KA
Sci Adv; 2019 Mar; 5(3):eaav6322. PubMed ID: 30944862
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity.
Martin AR; Pollack RA; Capoferri A; Ambinder RF; Durand CM; Siliciano RF
J Clin Invest; 2017 Feb; 127(2):651-656. PubMed ID: 28094770
[TBL] [Abstract][Full Text] [Related]
10. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
[TBL] [Abstract][Full Text] [Related]
11. Extracellular Vesicle Activation of Latent HIV-1 Is Driven by EV-Associated c-Src and Cellular SRC-1 via the PI3K/AKT/mTOR Pathway.
Barclay RA; Mensah GA; Cowen M; DeMarino C; Kim Y; Pinto DO; Erickson J; Kashanchi F
Viruses; 2020 Jun; 12(6):. PubMed ID: 32575590
[TBL] [Abstract][Full Text] [Related]
12. The Current Status of Latency Reversing Agents for HIV-1 Remission.
Rodari A; Darcis G; Van Lint CM
Annu Rev Virol; 2021 Sep; 8(1):491-514. PubMed ID: 34586875
[TBL] [Abstract][Full Text] [Related]
13. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
Gupta V; Dixit NM
PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
[TBL] [Abstract][Full Text] [Related]
14. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
15. Potential of Radiation-Induced Cellular Stress for Reactivation of Latent HIV-1 and Killing of Infected Cells.
Iordanskiy S; Kashanchi F
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):120-4. PubMed ID: 26765533
[TBL] [Abstract][Full Text] [Related]
16. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
Gohda J; Suzuki K; Liu K; Xie X; Takeuchi H; Inoue JI; Kawaguchi Y; Ishida T
Sci Rep; 2018 Feb; 8(1):3521. PubMed ID: 29476067
[TBL] [Abstract][Full Text] [Related]
17. G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells.
Piekna-Przybylska D; Bambara RA; Maggirwar SB; Dewhurst S
Cell Cycle; 2020 Sep; 19(18):2298-2313. PubMed ID: 32807015
[TBL] [Abstract][Full Text] [Related]
18. Selective cell death of latently HIV-infected CD4
Zhang G; Luk BT; Wei X; Campbell GR; Fang RH; Zhang L; Spector SA
Cell Death Dis; 2019 May; 10(6):419. PubMed ID: 31142734
[TBL] [Abstract][Full Text] [Related]
19. 4-phenylquinoline-8-amine induces HIV-1 reactivation and apoptosis in latently HIV-1 infected cells.
Kitamura H; Sukegawa S; Matsuda K; Tanimoto K; Kobayakawa T; Takahashi K; Tamamura H; Tsuchiya K; Gatanaga H; Maeda K; Takeuchi H
Biochem Biophys Res Commun; 2023 Jan; 641():139-147. PubMed ID: 36527748
[TBL] [Abstract][Full Text] [Related]
20. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
